Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lantern Pharma Inc.

3.79
-0.2000-5.01%
Post-market: 3.800.0100+0.26%17:59 EDT
Volume:452.88K
Turnover:1.78M
Market Cap:40.87M
PE:-2.05
High:3.98
Open:3.87
Low:3.55
Close:3.99
Loading ...

Lantern Pharma Q1 Net Income USD -4.5 Million

THOMSON REUTERS
·
15 May

Press Release: Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

Dow Jones
·
15 May

Lantern Pharma Reports Q1 2025 Results: R&D Expenses Down to $3.3M, Cash Reserves at $19.7M

Reuters
·
15 May

Lantern Pharma Q1 EPS $(0.42) Beats $(0.49) Estimate

Benzinga
·
15 May

Lantern Pharma Inc: Qtrly Shr Loss $0.42

THOMSON REUTERS
·
15 May

Lantern Pharma Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
13 May

Press Release: Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

Dow Jones
·
08 May

Lantern Advances Drug Candidate Lp-184 With Ind Clearance for Phase 1B/2 Clinical Trial in Triple Negative Breast Cancer (Tnbc)

THOMSON REUTERS
·
05 May

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

Business Wire
·
05 May

EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial

Benzinga
·
05 May

Lantern Pharma Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
05 May

Lantern Pharma initiated with a Buy at Lake Street

TIPRANKS
·
02 Apr

LTRN: 2024 Financial Results

Zacks Small Cap Research
·
28 Mar

Lantern Pharma Inc Qtrly EPS $-0.54

Reuters
·
28 Mar

Lantern Pharma Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Mar

Lantern Pharma Reports Q4 2024 Financial Results and AI Progress

TIPRANKS
·
28 Mar

Lantern Pharma Q4 2024 GAAP EPS $(0.54) Misses $(0.51) Estimate

Benzinga
·
28 Mar

Lantern Pharma Inc Qtrly EPS $-0.54

THOMSON REUTERS
·
28 Mar

Lantern Pharma reports Q4 EPS (54c) vs (39c) last year

TIPRANKS
·
28 Mar

Press Release: Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Dow Jones
·
28 Mar